antipyrine has been researched along with ketoconazole in 13 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 5 (38.46) | 18.7374 |
1990's | 1 (7.69) | 18.2507 |
2000's | 3 (23.08) | 29.6817 |
2010's | 3 (23.08) | 24.3611 |
2020's | 1 (7.69) | 2.80 |
Authors | Studies |
---|---|
Alvarez-Pedraglio, A; Colmenarejo, G; Lavandera, JL | 1 |
Artursson, P; Bergström, CA; Hoogstraate, J; Matsson, P; Norinder, U; Pedersen, JM | 1 |
Ahlin, G; Artursson, P; Bergström, CA; Gustavsson, L; Karlsson, J; Larsson, R; Matsson, P; Norinder, U; Pedersen, JM | 1 |
Afshari, CA; Eschenberg, M; Hamadeh, HK; Lee, PH; Lightfoot-Dunn, R; Morgan, RE; Qualls, CW; Ramachandran, B; Trauner, M; van Staden, CJ | 1 |
Cantin, LD; Chen, H; Kenna, JG; Noeske, T; Stahl, S; Walker, CL; Warner, DJ | 1 |
Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
Atiba, JO; Blaschke, TF; Pershe, RA; Taylor, G | 1 |
Bendikov, EA; Lapina, IZ; Leshchenko, VM; Petrakov, AV | 1 |
Bates, TR; D'Mello, AP; D'Souza, MJ | 1 |
Abernethy, DR; Blyden, GT; Greenblatt, DJ | 1 |
Daneshmend, TK; Ene, MD; Johnson, EM; Parker, G; Richardson, MD; Roberts, CJ; Warnock, DW | 1 |
Brennan, B; Ervine, CM; Houston, JB; Matthew, DE | 1 |
Cho, HY; Jeon, YH; Jung, K; Kim, HS; Kim, K; Kim, S; Kwon, NH; Lee, JY; Lee, S; Seo, B; Suh, YG | 1 |
1 trial(s) available for antipyrine and ketoconazole
Article | Year |
---|---|
Pharmacokinetics of ketoconazole-antipyrine interaction.
Topics: Adult; Antipyrine; Drug Interactions; Humans; Ketoconazole; Kinetics; Male | 1985 |
12 other study(ies) available for antipyrine and ketoconazole
Article | Year |
---|---|
Cheminformatic models to predict binding affinities to human serum albumin.
Topics: Adrenergic beta-Antagonists; Antidepressive Agents, Tricyclic; Chromatography, Affinity; Cyclooxygenase Inhibitors; Databases, Factual; Humans; Hydrophobic and Hydrophilic Interactions; Penicillins; Pharmaceutical Preparations; Protein Binding; Quantitative Structure-Activity Relationship; Reproducibility of Results; Serum Albumin; Steroids | 2001 |
Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).
Topics: Administration, Oral; Animals; Antineoplastic Agents; Antipsychotic Agents; Antiviral Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Biological Transport; Cell Line; Computer Simulation; Cytochrome P-450 Enzyme System; Drug-Related Side Effects and Adverse Reactions; Estradiol; Humans; Insecta; Liver; Models, Molecular; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Neoplasm Proteins; Pharmaceutical Preparations; Pharmacology; Structure-Activity Relationship | 2008 |
Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1.
Topics: Cell Line; Computer Simulation; Drug Design; Gene Expression Profiling; Humans; Hydrogen Bonding; Liver; Molecular Weight; Organic Cation Transporter 1; Pharmaceutical Preparations; Predictive Value of Tests; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Structure-Activity Relationship | 2008 |
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Assay; Biological Transport; Cell Line; Cell Membrane; Chemical and Drug Induced Liver Injury; Cytoplasmic Vesicles; Drug Evaluation, Preclinical; Humans; Liver; Rats; Reproducibility of Results; Spodoptera; Transfection; Xenobiotics | 2010 |
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Bile Acids and Salts; Cell Line; Chemical and Drug Induced Liver Injury; Humans; Quantitative Structure-Activity Relationship | 2012 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Plasma antipyrine half-life can be determined from urine data.
Topics: Adult; Aged; Antipyrine; Female; Half-Life; Humans; Interferons; Ketoconazole; Male; Middle Aged; Saliva | 1987 |
[Detoxifying function of the liver in patients with rubromycosis during treatment with antimycotics].
Topics: Adult; Antifungal Agents; Antipyrine; Female; Griseofulvin; Humans; Ketoconazole; Liver; Liver Function Tests; Male; Middle Aged; Saliva; Time Factors; Tinea | 1989 |
Ketoconazole does not impair antipyrine clearance in humans.
Topics: Adult; Aged; Antipyrine; Female; Half-Life; Humans; Ketoconazole; Male; Metabolic Clearance Rate; Middle Aged | 1986 |
Multiple dose pharmacokinetics of ketoconazole and their effects on antipyrine kinetics in man.
Topics: Adult; Antipyrine; Drug Interactions; Half-Life; Humans; Ketoconazole; Kinetics; Male; Metabolic Clearance Rate; Middle Aged | 1983 |
Comparison of ketoconazole and fluconazole as cytochrome P450 inhibitors. Use of steady-state infusion approach to achieve plasma concentration-response relationships.
Topics: Animals; Antifungal Agents; Antipyrine; Cytochrome P-450 Enzyme Inhibitors; Dose-Response Relationship, Drug; Enzyme Inhibitors; Fluconazole; Infusion Pumps; Ketoconazole; Liver; Male; Metabolic Clearance Rate; Rats; Rats, Sprague-Dawley | 1996 |
Discovery of novel potent migrastatic Thiazolo[5,4-b]pyridines targeting Lysyl-tRNA synthetase (KRS) for treatment of Cancer metastasis.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Movement; Cell Proliferation; Dose-Response Relationship, Drug; Drug Discovery; Drug Screening Assays, Antitumor; Enzyme Inhibitors; Female; Humans; Lysine-tRNA Ligase; Mammary Neoplasms, Experimental; Mice; Mice, Inbred BALB C; Molecular Structure; Pyridines; Structure-Activity Relationship | 2021 |